CLAIMS

1. A crystal of crystalline form 1 of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 1:2 HCl salt, characterized by an XRPD pattern comprising three or more peaks chosen from peaks (+/-5%) at 6.59°2θ, 7.40°2θ, 9.12°2θ, 14.57°2θ, 16.39°2θ, 26.06°2θ, 26.57°2θ, and 27.07°2θ.

2. The crystal of claim 1, characterized by an XRPD pattern comprising peaks (+/-5%) at 6.59°2θ, 7.40°2θ, 9.12°2θ, 14.57°2θ, 16.39°2θ, 26.06°2θ, 26.57°2θ, and 27.07°2θ.

3. The crystal of claim 1 or 2, characterized by an XRPD pattern the same as Figure 3A.

4. The crystal of any one of claims 1 to 3, having at least one characteristic chosen from a DSC thermogram the same as Figure 3C and a TGA profile the same as Figure 3B.

5. The crystal of any one of claims 1 to 4, wherein the XRPD pattern is obtained using CuKα radiation as an X-ray source.

6. A crystal of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide 1:2 HCl salt comprising at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% of the crystal of any one of claims 1 to 5.

7. A pharmaceutical composition comprising the crystal of any of the preceding claims and a pharmaceutically acceptable excipient.